IMNN Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Imunon, Inc.

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

8 days ago - By: Imunon, Inc.

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

11 days ago - By: Imunon, Inc.

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

12 days ago - By: Benzinga - Mentions: GALT ADAP PRME GNPX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

14 days ago - By: Imunon, Inc.

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

3 months ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

3 months ago - By: Stocktwits - Mentions: VXF

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

3 months ago - By: Imunon, Inc.

IMUNON Announces Reverse Stock Split

a month ago - By: Imunon, Inc.

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

a month ago - By: Imunon, Inc.

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

2 months ago - By: Imunon, Inc.

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Imunon, Inc.

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

3 months ago - By: Imunon, Inc.

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

3 months ago - By: Imunon, Inc.

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Imunon, Inc.

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

3 months ago - By: Imunon, Inc.

IMUNON Announces Stock Dividend Boosting Shareholder Value

3 months ago - By: Imunon, Inc.

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

4 months ago - By: Imunon, Inc.

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

4 months ago - By: Imunon, Inc.

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

5 months ago - By: Virtual Investor Conferences - Mentions: NIKA TIVC ADIA STSS ...

Life Sciences Investor Forum: Now Available for Online Viewing

5 months ago - By: Virtual Investor Conferences - Mentions: NIKA TIVC ADIA STSS ...

Life Sciences Investor Forum Agenda Announced for June 11th-12th

5 months ago - By: Imunon, Inc.

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

5 months ago - By: Imunon, Inc.

IMUNON INC (IMNN) Stock News

IMNN Latest News, Press Relases and Analysis

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

12 Health Care Stocks Moving In Wednesday's After-Market Session

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Earnings Scheduled For August 5, 2025

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

IMUNON Announces Reverse Stock Split

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

IMUNON Announces Stock Dividend Boosting Shareholder Value

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Life Sciences Investor Forum: Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for June 11th-12th

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS